Beam Therapeutics Inc. (BMV:BEAM)
Mexico · Delayed Price · Currency is MXN | Market Cap | 47.80B +54.2% |
| Revenue (ttm) | 2.96B +158.0% |
| Net Income | -1.19B |
| EPS | -11.58 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51 |
| Average Volume | 85 |
| Open | 460.00 |
| Previous Close | n/a |
| Day's Range | 460.00 - 460.00 |
| 52-Week Range | 309.00 - 604.00 |
| Beta | n/a |
| RSI | 46.19 |
| Earnings Date | Aug 5, 2026 |
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial numbers in USD Financial StatementsNews
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics licen...
Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Base editing programs show strong efficacy and safety in hematology and liver diseases, with lead assets advancing toward regulatory filings and broader patient reach. Accelerated approval is supported by robust biomarker data, and pricing will reflect long-term value.
Beam Therapeutics presents Phase 1/2 data for BEAM-302
Beam Therapeutics (BEAM) presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency at a symposium on translating scientific discovery in gene ed...
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Po...
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
Beam Therapeutics price target lowered to $39 from $40 at Bernstein
Bernstein analyst William Pickering lowered the firm’s price target on Beam Therapeutics (BEAM) to $39 from $40 and keeps an Outperform rating on the shares. Biotech has had a strong…
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
Beam Therapeutics reports Q1 EPS (91c), consensus ($1.01)
Reports Q1 revenue $31.74M, consensus $12.22M. “The first quarter of 2026 was a defining period for Beam, marked by meaningful clinical advances across our portfolio and key steps toward becoming…
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort ...
Beam Therapeutics Earnings release: Q1 2026
Beam Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q1 2026
Beam Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Beam Therapeutics rises 10.7%
Beam Therapeutics (BEAM) is up 10.7%, or $2.90 to $30.01.
Beam Therapeutics rises 10.8%
Beam Therapeutics (BEAM) is up 10.8%, or $2.91 to $30.02.
3 Biotech Stocks That Could Benefit from the Patent Cliff
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
Beam Therapeutics Proxy statement: Proxy filing
Beam Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Beam Therapeutics Proxy statement: Proxy filing
Beam Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Beam Therapeutics’ risto-cel shows efficacy in Sickle Cell Disease trial
Beam Therapeutics (BEAM) announced the publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel – risto-cel, formerly known as BEAM-101 – for the treat...
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics price target raised to $68 from $64 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Beam Therapeutics (BEAM) to $68 from $64 and keeps a Buy rating on the shares.
Clear Street sees buying opportunity for Beam Therapeutics after study update
Clear Street analyst Bill Maughan maintains a Buy rating and $37 price target on shares of Beam Therapeutics (BEAM) after the company reported Phase 1/2 data for BEAM-302 in Alpha-1…
Beam Therapeutics Transcript: Study result
BEAM-302 demonstrated robust efficacy and safety in 29 AATD patients, achieving durable, protective AAT levels and significant reduction of mutant Z-AAT with a single 60 mg dose. The therapy restored physiologic AAT regulation and showed a favorable safety profile, supporting advancement to pivotal trials.
Beam Therapeutics Press release: Study result
Beam Therapeutics issued a press release on March 25, 2026, disclosing material business information to investors.
Beam Therapeutics Slides: Study result
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
Beam Therapeutics (BEAM) announced updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 and the selection of 60 mg as the optimal biological dose to advance…